Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice

CompletedOBSERVATIONAL
Enrollment

93

Participants

Timeline

Start Date

January 10, 2018

Primary Completion Date

April 30, 2022

Study Completion Date

April 30, 2022

Conditions
Chronic Lymphocytic Leukemia
Trial Locations (13)

T2N 4Z6

University of Calgary /ID# 166416, Calgary

T6G 1Z2

Cross Cancer Institute /ID# 166417, Edmonton

T1J 1W5

Jack Ady Cancer Centre /ID# 217491, Lethbridge

R3E 0V9

CancerCare Manitoba /ID# 170751, Winnipeg

E1C 6Z8

The Moncton Hospital /ID# 166043, Moncton

B3H 1V7

QE II Health Sciences Centre /ID# 213548, Halifax

L6R 3J7

William Osler Health System /ID# 202049, Brampton

P3E 5J1

Health Sciences North /ID# 205817, Greater Sudbury

K7L 2V7

Kingston Health Sciences Centre /ID# 169252, Kingston

K1H 8L6

Ottawa Hospital Research Institute /ID# 166041, Ottawa

P7B 6V4

Thunder Bay Regional Research Institute /ID# 204740, Thunder Bay

H3T 1E2

Jewish General Hospital /ID# 166418, Montreal

G5L 5T1

CISSSBSL -Hopital regional de Rimouski /ID# 201202, Rimouski

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY